CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential...

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• CD123, the alpha subunit of the interleukin-3 receptor, is aberrantly expressed on neoplastic mast cells (MCs) in systemic mastocytosis (SM).
• Its absence on normal mast cells makes CD123 a promising therapeutic target in SM.

Purpose of the Study:

• To define CD123 expression patterns in systemic mastocytosis patients using immunohistochemistry.
• To investigate the clinical significance of CD123 expression and its association with plasmacytoid dendritic cells (PDCs).

Main Methods:

• Studied 58 systemic mastocytosis patients, classifying them into indolent SM (ISM), aggressive SM (ASM), SM with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
• Assessed CD123 expression on mast cells via immunohistochemistry, with slides scored independently by two hematopathologists.
• Evaluated the presence and extent of plasmacytoid dendritic cell (PDC) proliferation around mast cell aggregates.

Main Results:

• CD123 expression was observed in 64% of SM patients, with higher rates in ASM (100%) compared to ISM (61%) and SM-AHN (57%).
• Focal proliferation of PDCs was noted in 76% of cases and was significantly higher in CD123-positive (87%) versus CD123-negative (50%) cases.
• CD123 expression and staining intensity demonstrated prognostic value in specific SM subtypes.

Conclusions:

• CD123 targeting in SM may exert direct (via MCs) and indirect (via PDCs) antitumor effects.
• Observed heterogeneity in CD123 expression necessitates laboratory correlative studies for future clinical trials.
• Further research is warranted to explore the therapeutic potential of targeting CD123 in systemic mastocytosis.